Products for Out-Licensing

Products Available for Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at [email protected] to know more about NAL’s products and partnering opportunities.

 
Diabetes Type 2
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL3926 Semaglutide 1-Week Injection
ANDA
NAL3930 Tirepatide 1-Week Injection
ANDA
Top